REGN 8-K 2026-10-30

REGENERON PHARMACEUTICALS, INC. (REGN) 8-K dated 2026-10-30 — accession 0000872589-26-000032.

REGENERON PHARMACEUTICALS, INC. (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..

REGN: SECURITIES AND EXCHANGE COMMISSION

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 23.0.

Not investment advice. The REGN SEC hub lists recent forms. The stock page is the research view.